BioClinica eClinical Suite Chosen by Top BioTech Firm
BioClinica announced that Amarin Corporation has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions. Amarin Corporation is a late-stage biopharmaceutical company focused on the treatment of cardiovascular disease. The study is planned to involve approximately 300 sites and 8,000 patients globally.
BioClinica’s Trident IWR and EDC systems were selected based on BioClinica’s advanced technology portfolio, experience with large global trials; and cardiology expertise. BioClinica was able to build and deploy the study within 4 weeks.
“We are pleased that Amarin’s clinical development team selected an integrated solution from BioClinica that will seamlessly share essential clinical data while streamlining their clinical data and site management processes,” said Peter Benton, BioClinica’s President of eClinical Solutions. "In the last two quarters we have seen sponsors and CROs significantly increase their interest and investment in solutions that are not only “best-in-class” but also reduce the cost and hassle of unifying their clinical data to both manage their trials as well as readying their data for analysis.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
